Regimens Comparison for Breast Cancers of Positive Lymph Nodes
Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
positive lymph node
Study Type
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Epirubicin, CTX, Paclitaxel Type: Drug
Name: Epirubicin, Paclitaxel Type: Drug
Overall Status
To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes
Detailed Description
EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle *4cycle. followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle.

ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- patients with breast cancer after breast cancer surgery with positive lymph nodes age 18-70 years old

Exclusion Criteria:

- with other malignance disease
Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Beijing, China
Status: Recruiting
Contact: Peng Yuan, M.D. - 86-10-8778 8114 -
Start Date
May 2010
Completion Date
May 2020
Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences
Record processing date processed this data on July 28, 2015 page